Aap Implantate Ag · XETR:AAQ1

Aap Implantate — Q1 2017 Earnings Presentation

11 slides from Aap Implantate's earnings presentation, May 16, 2017

  1. Slide 1: aap Implantate AG Quarterly Statement Q1/2017 Conference Call

    aap Implantate AG Quarterly Statement Q1/2017 Conference Call Bruke Seyoum Alemu, CEO Marek Hahn, CFO Berlin, May 16, 2017

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Our publication may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual

  3. Slide 3: Implementation of Strategic Imperatives: Progress in Q1/2017

    Implementation of Strategic Imperatives Progress in Q1/2017 Products Customers Accelerating Value-based Innovation Enhancing Enhancing Market Market Access Access  LOQTEQ®: Completion of portfolio with a focus on the   Established Established countries: countries: Focus Share on DACH, Western Eur

  4. Slide 4: Financial Figures Q1/2017 (1/3)

    Financial Figures Q1/2017 (1/3) (in EUR million, sales bridge in KEUR) Sales Q1/2017 Q1/2016 Change Trauma 2.9 2.2 +30% thereof North America and Europe 2.1 1.8 +16% thereof RoW 0.8 0.4 +87% Other (mainly discontinued activities) 0.2 0.3 -34% Sales 3.1 2.5 +23% 4

  5. Slide 5: Financial Figures Q1/2017 (2/3)

    Financial Figures Q1/2017 (2/3) (in EUR million) EBITDA Q1/2017 Q1/2016 Change EBITDA -1.7 -2.2 +23% One-time effects 0.5 0.2 >100% Recurring EBITDA -1.2 -2.0 +39% One-time effects Q1/2017 Q1/2016 Project “Quality First” 0.2 0.0 Value depreciation raw materials 0.2 0.0 Pre-operating costs US sales 0

  6. Slide 6: Financial Figures Q1/2017 (3/3)

    Financial Figures Q1/2017 (3/3) (EBITDA bridge Q1/2016 to Q1/2017 in KEUR) 6

  7. Slide 7: Highlights Q1/2017 (Balance Sheet)

    Highlights Q1/2017 (Balance Sheet) • Total assets 03/31/2017: EUR 61,5 million (12/31/2016: EUR 63,9 million)  -4%  Non-current assets: Change EUR -0.2 million  Capitalized development costs: EUR +0.1 million  Share of intangible assets in total assets: 18%  Healthy ratio  Tangible assets: EUR

  8. Slide 8: Highlights Q1/2017 (Cash Flow)

    Highlights Q1/2017 (Cash Flow) • Operating Cash Flow Q1/2017: EUR -1.2 million (Q1/2016: EUR -2.7 million)  Positive contribution from working capital reduction of KEUR 412  main impact reduction of inventory of EUR 0.7 million  Stringent and improved debtor management leads to unchanged level of

  9. Slide 9: Outlook FY/2017

    Outlook FY/2017 Q2/2017 – Sales: EUR 1.8 million – EUR 2.7 million (Q2/2016: Reported EUR 3.4 million)* – EBITDA: EUR -1.7 million – EUR -1.3 million (Q2/2016: Reported EUR -1.4 million) FY/2017 – Sales: EUR 10.0 million – EUR 13.0 million (FY/2016: EUR 10.5 million) – EBITDA: EUR -6.5 million – EUR

  10. Slide 10: Management Agenda 2017 and beyond

    Management Agenda 2017 and beyond Implementation of strategic imperatives Products Customers Accelerating Value-based Innovation Enhancing Enhancing Market Market Access Access  LOQTEQ®: Completion of LOQTEQ® portfolio with a focus   Established Established countries: countries: Focus Focus on on

  11. Slide 11: Many thanks for your attention!

    Many thanks for your attention! Lorenzweg 5 • 12099 Berlin • Germany Fabian Franke Manager Investor Relations Tel.: +49 30 750 19 – 134 Fax: +49 30 750 19 – 290 E-Mail: ir@aap.de IR-app: 11

aap Implantate — Q1 2017 Earnings Presentation on 6ix